Some applications of the present invention relate in general to valve replacement. More specifically, some applications of the present invention relate to prosthetic cardiac valves and techniques for implantation thereof.
Ischemic heart disease causes regurgitation of a heart valve by the combination of ischemic dysfunction of the papillary muscles, and the dilatation of the ventricle that is present in ischemic heart disease, with the subsequent displacement of the papillary muscles and the dilatation of the valve annulus.
Dilation of the annulus of the valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium.
For some applications of the invention, a prosthetic valve support is provided for facilitating minimally invasive (e.g., transcatheter and/or transluminal) implantation of a prosthetic valve at a native valve of a subject. The native valve typically has native check valve functionality, i.e., it functions as a check valve. The prosthetic valve support is typically couplable to the native valve (e.g., to leaflets thereof) of the subject without eliminating the check valve functionality of the native valve. The prosthetic valve is subsequently implanted at the native valve by coupling the prosthetic valve to the prosthetic valve support, typically by expanding the prosthetic valve within an opening defined by the prosthetic valve support. The implantation of the prosthetic valve at the native valve replaces, at least in part, the check valve functionality of the native valve with substitute check valve functionality of the prosthetic valve. The prosthetic valve support comprises an upstream support portion, configured to be placed against an upstream surface of the native valve, and shaped to define an opening.
For some applications, the upstream support portion is delivered to the native valve in a delivery configuration (e.g., rolled within a delivery tube), and the tissue-engaging elements comprise tissue anchors that are driven through the upstream support portion and into the annulus of the native valve while at least part of the upstream support portion is still within the delivery tube (e.g., is still in the delivery configuration).
For some applications, the prosthetic valve support comprises tissue-engaging elements, such as clips. For some such applications, the clips comprise two arms, and a fabric which covers the arms, and typically has a greater surface area than the clip arms. The fabric is configured to cushion (e.g., soften and/or disperse) forces applied by the clips on the tissue to which the clip is coupled. The clips of the prosthetic valve support are typically coupled to leaflets of the native valve and are further typically configured to move with the native beating of the leaflets so as not to eliminate the check valve functionality of the native valve.
For some applications, tissue-engaging elements are coupled to the native valve (e.g., to the leaflets thereof) and the upstream support portion is subsequently coupled to the tissue-engaging elements. For such applications, each tissue-engaging element is typically coupled to a longitudinal guide member along (e.g., over) which the upstream support portion is slidable. For some such applications, the tissue-engaging elements comprise clips, configured to be coupled to the leaflets of the native valve. For some such applications, the tissue-engaging elements comprise tissue anchors that are coupled to the annulus.
For some applications in which the tissue-engaging elements comprise tissue anchors, more than one tissue anchor is delivered through one delivery tube. For example, the anchors may each fit snugly through the delivery tube, and be delivered sequentially.
As described hereinabove, a prosthetic valve is typically coupled to the prosthetic valve support after the prosthetic valve support has been coupled to the native valve. For some applications, the prosthetic valve comprises a valve body, and a downstream portion that is configured to inhibit contact between chordae tendineae of the heart and the valve body, such as to prevent damage to the chordae tendineae. Typically, an outer surface of the downstream portion is covered with a fabric. For some applications, the prosthetic valve comprises a valve body that comprises an upstream portion, a downstream portion, and an elastic portion between the upstream portion and the downstream portion. For some such applications, the prosthetic valve is configured to facilitate coupling of a pre-determined portion of the prosthetic valve to the prosthetic valve support (e.g., to the upstream support portion thereof).
There is therefore provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve at a native valve of a heart of a subject, the apparatus including:
a delivery tube, transluminally advanceable to the heart of the subject;
a prosthetic valve support, configured to support the prosthetic valve at the native valve, and including an upstream support portion, the upstream support portion:
a tissue anchor, configured to be disposed within the channel, and slidable through at least part of the channel; and
an anchor driver, slidable within the delivery tube and the channel, and configured to anchor the upstream support portion to tissue of the heart by driving the tissue anchor from the opposing side through the upstream support portion and into the tissue, while at least part of the upstream support portion is disposed within the delivery tube.
In an application, the tissue anchor includes a helical tissue anchor, and is configured to be driven into the tissue by being rotated.
In an application, the upstream support portion is configured to be transitioned from the delivery configuration to the working configuration by being unrolled.
In an application:
in the delivery configuration, the upstream support portion has a distal portion and a proximal portion, and the channel is defined between the distal portion and the proximal portion,
the anchor includes a first anchor, and the anchor driver is configured to anchor the distal portion of the upstream support portion to the tissue by driving the first anchor through the distal portion of the upstream support portion, and
the apparatus is configured such that:
In an application, in the delivery configuration, the upstream support portion has a distal portion and a proximal portion, and shapes the channel to be an uninterrupted lumen between the distal portion and the proximal portion.
In an application, the anchor driver is configured to slide the tissue anchor through at least most of the channel before driving the anchor through the upstream support portion.
In an application, the delivery tube is configured to be transluminally advanced while the upstream support portion is disposed within a distal portion of the delivery tube, and while the tissue anchor and a distal portion of the anchor driver are disposed within the channel.
In an application, the delivery tube is configured to retain the upstream support portion in the delivery configuration, and the upstream support portion is configured to automatically transition toward the working configuration upon becoming exposed from the delivery tube.
In an application, in the delivery configuration, at any given part of the upstream support portion, the opposing side of the upstream support portion is disposed closer to the central longitudinal axis than is the tissue-contacting side.
In an application, while the upstream support portion is in the delivery configuration and disposed within the delivery tube, the channel shares a common central longitudinal axis with the delivery tube, and the anchor driver is configured to drive the tissue anchor through the upstream support portion by moving the tissue anchor along the common central longitudinal axis.
In an application, the delivery tube is configured to facilitate the driving of the tissue anchor through the upstream support portion by deflecting a portion of the prosthetic valve support to intersect with the common central longitudinal axis by pressing the portion of the prosthetic valve support against the tissue.
There is further provided, in accordance with an application of the present invention, a method for anchoring a prosthetic valve support to a native valve of a heart of a subject, the native valve having an annulus and a plurality of leaflets, the prosthetic valve support including an upstream support portion that is configured to be placed against an atrial surface of the annulus, the method including:
transluminally advancing, to the heart of the subject, the upstream support portion, while the upstream support portion (1) is in a delivery configuration thereof in which the upstream support portion has a distal portion and a proximal portion, and defines a channel therebetween, and (2) is disposed within a delivery tube;
advancing, out of a distal end of the delivery tube, the distal portion of the upstream support portion;
using an anchor driver at least a distal end of which is disposed within the channel, anchoring the distal portion of the upstream support portion to a site of the annulus by driving an anchor through the distal portion of the upstream support portion and into the site; and
subsequently, facilitating transition of the upstream support portion into a working configuration in which the upstream support portion is generally annular, and is disposed against the annulus.
In an application, transluminally advancing the upstream support portion includes transluminally advancing the delivery tube while the upstream support portion is disposed within a distal portion of the delivery tube, and while the tissue anchor and a distal portion of the anchor driver are disposed within the channel.
In an application, facilitating transition of the upstream support portion into the working configuration includes facilitating unrolling of the upstream support portion into the working configuration.
In an application, facilitating transition of the upstream support portion into the working configuration includes exposing the upstream support portion from the delivery tube such that the upstream support portion transitions automatically into the working configuration.
In an application, the method further includes advancing the tissue anchor through at least most of the channel prior to anchoring the distal portion.
In an application:
the anchor includes a first anchor, and the site includes a first site, and
the method further includes, subsequently to anchoring the distal portion, sliding the anchor driver proximally within the channel and subsequently anchoring, using a second anchor, a proximal portion of the upstream support portion to a second site of the annulus.
In an application, the method further includes pressing the distal portion against the site such that a plane of the distal portion is disposed at greater than 45 degrees with respect to a longitudinal axis of the delivery tube.
In an application:
while the upstream support portion is in the delivery configuration and disposed within the delivery tube, the channel shares a common central longitudinal axis with the delivery tube, and
driving the anchor through the distal portion includes driving the anchor through the distal wall by moving the tissue anchor along the common central longitudinal axis.
In an application:
the method further includes pressing the distal portion against the site such that the distal portion deflects with respect to a central longitudinal axis of the channel, and
driving the tissue anchor through the distal portion includes moving the anchor driver distally within the channel while the distal portion is pressed against the site.
There is further provided, in accordance with an application of the present invention, a method for anchoring a prosthetic valve support to a native valve of a heart of a subject, the native valve having an annulus and a plurality of leaflets, the prosthetic valve support including an upstream support portion that is configured to be placed against an atrial surface of the annulus, the method including:
transluminally advancing, to the heart of the subject, the upstream support portion, while the upstream support portion (1) is in a delivery configuration thereof in which the upstream support portion generally defines a tube that defines a channel, and (2) is disposed within a delivery tube;
advancing, out of a distal end of the delivery tube, a distal portion of the upstream support portion in the delivery configuration thereof;
anchoring the distal portion to a first site of the annulus using an anchor that is reversibly coupled to an anchor driver, by moving the anchor driver distally within the channel of the tube defined by the upstream support portion; and
facilitating unrolling of the upstream support portion into a deployed configuration in which the upstream support portion is generally annular, and is disposed against the annulus.
In an application, the anchor includes a first anchor, and the method further includes anchoring, using a second anchor, a proximal portion of the upstream support portion to a second site of the annulus.
In an application, anchoring the distal portion of the upstream support portion to the first site includes bending the distal portion by pressing the distal portion against the first site, such that moving the anchor driver distally within the channel of the tube defined by the upstream support portion moves the anchor through the distal portion.
In an application, the method further includes pressing the distal portion against the first site such that a plane of the distal portion is disposed at greater than 45 degrees with respect to a longitudinal axis of the delivery tube.
There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of an implant at a native valve of a heart of a subject, the apparatus including a tissue-engaging element, the tissue-engaging element including:
a first portion of the apparatus, including:
a second portion of the apparatus,
the first end of the arm of the first portion being articulatably coupled to the second portion at a hinge region, and the tissue-engaging element being configured to sandwich tissue in a vicinity of the native valve between the fabric and the second portion of the apparatus.
In an application, the tissue-engaging element is configured to sandwich tissue of the native valve between the fabric and the second portion of the apparatus.
In an application, the area of the fabric is more than twice as great as the area of the face.
In an application, the fabric entirely covers the face.
In an application, the apparatus further includes the implant, and the second portion of the apparatus includes a portion of the implant.
In an application, the fabric is generally shaped to define a saddle shape having a saddle point, the saddle point being disposed in a vicinity of the hinge region.
In an application:
the arm of the first portion includes a first arm, and the face of the first arm includes a first face,
the second portion of the apparatus includes a second arm, having:
the first end of the second arm is articulatably coupled to the first end of the first arm at the hinge region,
the fabric is coupled to the first arm and to the second arm, and is disposed over the first face and the second face, and
the area of the fabric is greater than the sum of the area of the first face and the area of the second face.
In an application, the first face extends laterally from the longitudinal axis of the first arm, the second face extends laterally from the longitudinal axis of the second arm, and the fabric extends further from the longitudinal axis of each of the first and second arms than does the width of the first and second faces, respectively.
In an application, the fabric extends, from the hinge region, further along the longitudinal axis of the first arm than does the first face.
In an application, a portion of the fabric is disposed over a second end of the first arm.
In an application, the portion of the fabric that is disposed over the second end of the first arm defines at least part of a cushion.
In an application, the cushion extends, from the second end of the first arm, away from the second arm.
There is further provided, in accordance with an application of the present invention, apparatus, for implantation at a native valve of a heart of a subject, the native valve including at least a first valve leaflet and a second valve leaflet, each leaflet being coupled to a respective plurality of chordae tendineae, the apparatus including:
a prosthetic valve, including:
In an application, the downstream portion includes a frame, and at least an outer surface of the frame is covered with a covering.
In an application, the downstream portion is tubular, and the downstream portion and the valve body define a continuous lumen therethrough.
In an application, the heart of the subject includes a plurality of papillary muscles, and at least part of the downstream portion is configured to be placed in contact with at least one of the papillary muscles.
In an application, the downstream portion includes one or more protrusions, each protrusion extending away from the downstream end of the valve body.
In an application, the valve body has a longitudinal axis therethrough, and includes a circumferential lateral wall that defines a curved plane that circumscribes the longitudinal axis, and the protrusions lie on the plane.
In an application, each protrusion has a transverse cross-sectional shape of an arc, and the arc of each protrusion lies on the curved plane defined by the valve body.
There is further provided, in accordance with an application of the present invention, apparatus, for implantation at a native valve of a heart of a subject, the native valve being disposed between an atrium and a ventricle of the heart, the apparatus including:
a tubular valve body:
at least one valve member, disposed in the lumen of the valve body, and configured to facilitate flow of blood of the subject from the upstream portion of the valve body to the downstream portion of the valve body, and to inhibit flow of the blood from the downstream portion of the valve body to the upstream portion of the valve body.
In an application, the at least one valve member is coupled to the downstream portion of the valve body.
In an application, the native valve includes a plurality of native leaflets, and the downstream portion of the valve body is configured to be coupled to the native leaflets.
In an application, the apparatus further includes a plurality of clips, configured to facilitate the coupling of the downstream portion of the valve body to the native leaflets.
In an application, each clip:
includes at least two clip arms, articulatably coupled to each other, and
is reversibly closeable.
In an application, the clips are coupled to the downstream portion of the valve body, and the downstream portion of the valve body is configured to be coupled to the native leaflets by the clips being coupled to the native leaflets.
In an application, each clip of the plurality of clips is articulatably coupled to the downstream portion of the valve body.
In an application, the native valve includes an annulus having an upstream surface, and the apparatus further includes a prosthetic valve support:
including (1) an upstream support portion, configured to be placed against the upstream surface of the annulus of the native valve, and (2) the plurality of clips, coupled to the upstream support portion, and
shaped to define an opening therethrough that is configured to receive the prosthetic valve,
and the clips are configured to facilitate the coupling of the downstream portion of the valve body to the native leaflets by coupling the prosthetic valve support to the native leaflets.
There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of a prosthetic valve at a native valve of a heart of a subject, the native valve having a plurality of native leaflets, the apparatus including:
at least one tissue-engaging element, configured to be transluminally delivered to the native valve, and to be coupled to a native leaflet of the subject;
an upstream support portion, configured to be transluminally delivered to the native valve, and to be intracorporeally coupled to the tissue-engaging element;
at least one locking element, configured to intracorporeally couple the tissue-engaging element to the upstream support portion such that the tissue-engaging element is movable with respect to the upstream support portion.
In an application, the tissue-engaging element includes a clip, having at least a first arm and a second arm, the first and second arms being articulatably coupled to each other, and the clip is reversibly openable and closeable.
In an application:
the first arm has a first face and the second arm has a second face,
the tissue-engaging element includes a fabric that is coupled to the first arm and to the second arm, and is disposed over the first face and the second face, and the fabric defines an area that is greater than the sum of the area of the first face and the area of the second face.
In an application, the apparatus further includes a clip controller, configured to interface with the clip, and to facilitate the reversible opening and closing of the clip.
In an application, the apparatus further includes at least one flexible longitudinal guide member, and the apparatus is configured such that, when the locking element couples the tissue-engaging element to the upstream support portion, at least a portion of the flexible longitudinal guide member is disposed between the tissue-engaging element and the upstream support portion.
In an application:
the flexible longitudinal guide member is coupled to the locking element and to the tissue-engaging element,
the locking element is configured to couple the tissue-engaging element to the upstream support portion by the locking element being coupled to the upstream support portion, and
flexibility of the at least the portion of the flexible longitudinal guide member facilitates the coupling of the tissue-engaging element to the upstream support portion such that the tissue-engaging element is movable with respect to the upstream support portion.
There is further provided, in accordance with an application of the present invention, a method for anchoring a prosthetic valve support to a native valve of a subject, the native valve having an annulus and a plurality of leaflets, the method including:
transluminally advancing a delivery tube such that a distal end of the delivery tube is disposed in a vicinity of a first site of the annulus;
advancing a first anchor distally through the delivery tube by advancing an anchor driver through the delivery tube, the anchor driver having a distal end to which the first anchor is reversibly coupled, and the first anchor being coupled to a distal end of a first guide member;
anchoring the first anchor to tissue of the first site of the annulus using the anchor driver;
subsequently, decoupling the anchor driver from the first anchor, and proximally withdrawing the anchor driver such that at least a portion of the first guide member remains disposed within the delivery tube, and such that the distal end of the first guide member remains coupled to the first anchor;
subsequently, advancing a second anchor through the delivery tube such that the second anchor passes at least the portion of the first guide member, the second anchor being coupled to a distal end of a second guide member;
positioning the distal end of the delivery tube in a vicinity of a second site of the annulus; and
anchoring the second anchor to tissue of the second site of the annulus;
sliding the prosthetic valve support distally over the first guide member and the second guide member; and
anchoring the prosthetic valve support to the native valve by inhibiting further sliding of the prosthetic valve support with respect to the first guide member and the second guide member.
In an application:
transluminally advancing the delivery tube includes transluminally advancing a delivery tube through which the first anchor fits snugly and through which the second anchor fits snugly,
advancing the first anchor distally through the delivery tube includes advancing the first anchor distally through the delivery tube in which the first anchor fits snugly, and
advancing the second anchor distally through the delivery tube includes advancing the second anchor distally through the delivery tube in which the second anchor fits snugly.
In an application, advancing the anchor driver through the delivery tube includes advancing the anchor driver through a delivery tube through which the anchor driver fits snugly.
In an application, advancing anchor driver includes advancing an anchor driver that has a transverse cross-sectional area that is more than twice as great as a transverse cross-sectional area of the first guide member.
In an application, anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support include anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support without eliminating movement of the leaflets of the native valve.
In an application, anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support include anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support without engaging the leaflets of the native valve.
In an application, anchoring the first anchor at the first site of the annulus includes anchoring the first anchor at a first site of the annulus that is in the vicinity of a first commissure of the native valve, and anchoring the second anchor at the second site of the annulus includes anchoring the second anchor at a second site of the annulus that is in the vicinity of a second commissure of the native valve.
In an application, the method further includes advancing a guidewire to the first commissure of the native valve, the delivery tube being shaped to define a lateral opening through which the guidewire is slidable, and transluminally advancing the delivery tube to the first site of the annulus includes sliding the delivery tube over the guidewire.
In an application, transluminally advancing the delivery tube to the first site that is in the vicinity of the first commissure includes transluminally advancing the delivery tube to a first site that is a distance from the first commissure, the distance of the first site from the first commissure being at least in part dependent on a distance between the distal end of the delivery tube and the lateral opening of the delivery tube.
The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:
Reference is made to
Tissue-engaging element 24 (e.g., tissue-engaging elements 24a, 24b, and 24c) comprises at least one arm 26. Typically, element 24 comprises two arms 26 (e.g., a first arm 26x and a second arm 26y), which are articulatably coupled to each other at a hinge region 34. Each arm 26 has a length from a first end 28 thereof at hinge region 34, to a second end 30 thereof, and a longitudinal axis therebetween. Each arm 26 also has a face 32, which has a length along the longitudinal axis of the arm, a width that is orthogonal to the length, and an area defined by the width and the length.
Tissue-engaging element 24 is configured to sandwich tissue in the vicinity of the native heart valve using the at least one arm 26. Typically, element 24 is configured to sandwich the tissue between first arm 26x and second arm 26y. Alternatively, element 24 may comprise only one arm (e.g., arm 26x), coupled to another portion of the apparatus (e.g., a portion of implant 22), and may be configured to sandwich the tissue between arm 26x and the other portion of the apparatus. Typically, and as shown in
Tissue-engaging element 24 further comprises a fabric 40, coupled to arm 26 so as to have a length and a width that define an area of the fabric (e.g., an area of the fabric that is disposed over face 32). Typically, the area of fabric 40 is greater than the area of face 32, such that part of the fabric is disposed over face 32, and part of the fabric extends past the face. For example,
It is to be noted that throughout this patent application, including the specification and the claims, the term “fabric” typically means a woven fabric, but may also include other sheet-like materials, such as sheets of polymer and/or silicone.
For some applications, the area of fabric 40 is more than twice as great as the area of face 32. For some applications, the fabric entirely covers face 32. Alternatively, fabric 40 may be shaped to define a hole 42 through which a portion of arm 26 (e.g., a portion of face 32 thereof) may contact the tissue being sandwiched (e.g., the tissue of the native leaflet). For example, and as shown in
Typically, tissue-engaging elements 24 comprise two arms (e.g., arms 26x and 26y) and two respective faces 32, and fabric 40 spans both faces, and is bent (e.g., folded) to define a trough 48 in the vicinity of hinge region 34, thereby forming a clip with two tissue-engaging surfaces comprising fabric 40, and corners 50 that define respective ends of the trough. Typically, the area of fabric 40 is greater than (e.g., more than twice as great as) the sum of the respective areas of both faces 32, and thereby at least part (e.g., more than half) of fabric 40 is not directly backed by an arm (e.g., a face thereof), thereby providing flexibility to the clip. For some applications, and as shown in
As shown in the magnified area of
Typically, and as shown in
For some applications, and as shown in
For some applications, tissue-engaging elements 24 are articulatably coupled to upstream support portion 62 such that, when prosthetic valve support 60 is coupled to the native valve, native movement (e.g., beating) of the leaflets of native valve 10 is not eliminated, and thereby check-valve functionality of the native valve is not eliminated. For some such applications, prosthetic valve support is thereby implantable without the use of cardiopulmonary bypass.
Reference is made to
Typically, valve body 104 comprises a frame 112, such as a stent-like wire frame. For some applications, and as shown in
Typically, apparatus 100 (e.g., prosthetic valve 102 thereof) comprises a covering 114, disposed over (e.g., covering) an inner surface of frame 112. Typically, covering 114 is also disposed over an inner surface of downstream portion 106. Further typically, covering 114 is also disposed over an outer surface of portion 106 (e.g., extends around a distal end of apparatus 100). Sections A-A of
As described hereinabove, downstream portion 106 is configured to inhibit contact between chordae tendineae 86 and valve body 104. As shown in
Reference is made to
As shown in
Typically, locking element 146 comprises a ratcheting element 158, comprising a plurality of ratchet teeth 160. Further typically, system 140 (e.g., prosthetic valve support 150 thereof) comprises a plurality of longitudinal guide members 162, each longitudinal guide member coupled to a respective tissue-engaging element, and each locking element 146 (e.g., ratcheting element 158) is coupled to and/or defined by a respective longitudinal guide member. Upstream support portion 142 is slidable along longitudinal guide members 162 (e.g., each longitudinal guide member is slidable through a respective hole 164 defined by the upstream support portion), typically by being pushed along the longitudinal guide members by one or more pushers 168 that are themselves typically slidable over the longitudinal guide members. Such sliding is typically facilitated by providing a counter force by simultaneous pulling on longitudinal guide members 162.
As shown in
Coupling of upstream support portion 142 to tissue-engaging elements 144 thereby forms prosthetic valve support 150. Typically, tissue-engaging elements 144 are flexibly coupled to upstream support portion 142 (i.e., can move with respect to the upstream support portion while coupled to the upstream support portion). For example, longitudinal guide members 162 are typically flexible, and a portion of each flexible longitudinal guide member is disposed between a respective tissue-engaging element 144 (i.e., the point at which the longitudinal guide member is coupled to the tissue-engaging element) and upstream support portion 142 (i.e., the point at which the longitudinal guide member is coupled to the upstream support portion). Such coupling typically configures prosthetic valve support 150 to be couplable to native valve without eliminating the valve function thereof, e.g., as described hereinabove. Upstream support portion 142 is typically annular, and shaped to define an opening therethrough, through which blood may flow.
Typically, a proximal portion of each longitudinal guide member 162 is decoupled from a distal portion of that longitudinal guide member and/or from the respective locking element 146, such as, but not limited to, by cutting. Such decoupling may be performed before introduction of prosthetic valve 148, as shown, or subsequently thereto.
Subsequently to coupling of upstream support portion 142 to tissue-engaging elements 144 (and thereby formation of prosthetic valve support 150), prosthetic valve 148 is delivered to native valve 10 and coupled to the tissue-engaging elements (e.g., to the prosthetic valve support) (
Reference is made to
Prosthetic valve 180 is shaped to define a continuous lumen through portions 184, 188, and 186. Prosthetic valve 180 is configured to be implanted at native valve 10 such that an upstream portion 184 is disposed in an atrium 6 of the heart of the subject, and such that downstream portion 186 is disposed in a ventricle 8 of the heart of the subject. For example, prosthetic valve 180 may be coupled to a prosthetic valve support 190 that has previously coupled to the native valve. Prosthetic valve support 190 typically comprises tissue-engaging elements 144, upstream support portion 142, and stabilizing member 154, described hereinabove. For some applications, prosthetic valve support 190 comprises prosthetic valve support 150, described hereinabove. For some applications, prosthetic valve support 190 comprises a prosthetic valve support that comprises tissue-engaging elements 144, upstream support portion 142, and stabilizing member 156 that are provided pre-coupled to each other. For some applications, prosthetic valve support 190 may comprise another prosthetic valve support.
Tubular valve body 182 typically comprises a frame 192, such as a stent-like wire frame. As shown in
Typically, prosthetic valve 180 comprises an expandable prosthetic valve, and is deployed such that it (1) expands within the opening defined by upstream support portion 142 and/or the opening defined by stabilizing member 154, (2) applies a radially-expansive force against the upstream support portion and/or the stabilizing member, and (3) thereby becomes coupled thereto. Typically, and as shown in
Reference is made to
Reference is now made to
A tissue anchor 220 (e.g., a first tissue anchor 220a) is advanced through at least a distal portion of tube 206, and is anchored to tissue of the native valve, such as tissue of the annulus of the native valve (state A). Typically, anchor 220 is advanced using an elongate anchor driver 222. For some applications, anchor 220 comprises a helical anchor, and is anchored to the tissue by being rotated using anchor driver 222.
Anchor driver 222 is reversibly coupled to anchor 220a, and is subsequently decoupled from the anchor and withdrawn proximally (e.g., withdrawn from the body of the subject) (state B). Anchor 220a is coupled to a longitudinal guide member 224 (e.g., a first guide member 224a), which is exposed from a lumen of anchor driver 222 when the driver is withdrawn (i.e., is slid proximally off of member 224). It is to be noted that at least a portion of guide member 224a remains disposed within tube 206. Tube 206 is moved toward a second commissure 14 of valve 10, and positioning of the tube is typically facilitated by guidewire 208 being disposed between leaflets 12 at the commissure, as described hereinabove.
A tissue anchor 220 (e.g., a second tissue anchor 220b) is advanced through at least a distal portion of tube 206, and is anchored to tissue of the native valve, such as tissue of the annulus of the native valve (state B). Typically, anchor 220b is advanced using an elongate anchor driver, such as the same anchor driver 222, or a second anchor driver. It is to be noted that anchor 220 and anchor driver 222 are advanced through tube 206 while at least a portion of first guide member 224a is disposed within tube 206 (i.e., advanced past at least a portion of member 224a).
Anchor driver 222 is subsequently decoupled from anchor 220b and is withdrawn proximally (e.g., withdrawn from the body of the subject) (state C). Anchor 220b is coupled to a longitudinal guide member 224 (e.g., a second guide member 224b), which is exposed from the lumen of anchor driver 222 when the driver is withdrawn. Native valve is thereby left with respective distal ends of two guide members 224 coupled thereto (e.g., coupled to the annulus thereof) (state D).
Reference is now made to
Subsequently, prosthetic valve support 202 is anchored to native valve 10 by inhibiting movement of the prosthetic valve support with respect to guide members 224. For example, a stopper 228 may be slid along each guide member and fastened to the guide member in the vicinity of the prosthetic valve support. For some applications, each guide member 224 comprises two discrete filaments, each filament being slidable through a separate hole in the prosthetic valve support, and the prosthetic valve support is anchored by tying the filaments together, optionally facilitated by a pledget (not shown). Typically, a proximal portion of each guide member is subsequently removed, such as by decoupling that portion from a distal portion, e.g., by cutting.
Reference is now made to
Reference is again made to
For some applications, anchor 200, prosthetic valve support 202 in the compressed configuration thereof, and prosthetic valve 230 in the compressed configuration thereof, have respective transverse cross-sectional areas that are generally the same as each other (e.g., having a difference of less than 50%, such as less than 30%, such as less than 10%). For example, prosthetic valve support in the compressed configuration is typically less than 50% (e.g., less than 30%, such as less than 10%) wider than each anchor 200. For some such applications, this provides an efficient use of space within delivery tube 206, and thereby allows the use of a narrow delivery tube, e.g., because none of the anchor, support, or valve are more than 50% wider than another. In contrast, for some applications in which two or more anchors and/or anchor drivers are delivered in parallel, a delivery tube would have to be significantly wider than (e.g., twice as wide as) the delivery tube of system 200.
Reference is made to
State B of
The upstream support portion configurations in
Upstream support portion 254 has a tissue-contacting side 274, configured to be placed against the atrial surface of valve 10 (e.g., against the annulus of the valve), and an opposing side 276, and defines an opening 278 therebetween. It is to be noted that, in the delivery configuration, opposing side 276 is disposed closer to central longitudinal axis 258 than is tissue-contacting side 274.
Reference is again made to
Typically, distal portion 260 is anchored by (1) exposing the distal portion from delivery tube 256 and pressing it against the tissue of the annulus such that it deflects (e.g., bends) back and is disposed generally in front of the channel defined by the remainder of the upstream support portion that is disposed in the delivery configuration within tube 256, and (2) advancing anchor 280 distally through the upstream support portion (i.e., through distal portion 260 thereof) and into the tissue. For some applications, a plane defined by the distal portion is disposed at greater than 45 degrees with respect to longitudinal axis 258.
For some applications, during transluminal advancement, anchor 280a is disposed proximally to upstream support portion 254 (e.g., within a proximal portion of the delivery tube, or outside of the body of the subject), and driver 272 subsequently moves the anchor from a proximal end of the channel defined by the upstream support portion, through the channel. That is, driver 272 may slide anchor 280a past at least part of the longitudinal axis of upstream support portion 254 (e.g., past most of the longitudinal axis of the upstream support portion, such as past at least 80 percent of the longitudinal axis of the upstream support portion). Alternatively, during transluminal advancement, anchor 280a and a distal portion of anchor driver 272 may be already disposed within the channel defined by the upstream support portion, and the driver subsequently moves anchor 280a only slightly distally so as to drive the anchor through distal portion 260 and into the tissue. For some such applications, the delivery tube is transluminally advanced while the upstream support portion is disposed within a distal portion of the delivery tube, and the tissue anchor and the distal portion of the anchor driver are disposed within the channel.
Subsequently, upstream support portion 254 is further exposed from delivery tube 256 (e.g., by withdrawing the delivery tube proximally), and the distal end of the delivery tube is moved toward a second site of the annulus (state B). As upstream support portion 254 is progressively exposed from delivery tube 256, the upstream support portion typically progressively transitions (e.g., expands and/or unrolls) automatically toward the working configuration thereof. To facilitate such automatic transition toward the working configuration, upstream support portion 254 may comprise a frame (e.g., comprising a shape-memory material such as nitinol), which may be covered in a covering, such as a fabric.
Subsequently, a proximal portion 262 of upstream support portion 254 is anchored to the second site using a tissue anchor 280 (e.g., a second tissue anchor 280b) in a similar manner to that described for distal portion 260 (state C). Typically, during anchoring of proximal portion 262, the proximal portion is held near the distal end of delivery tube 256 by a deployment tool (e.g., slightly inside the delivery tube or just outside of the delivery tube). The deployment tool is not visible in state C; it is obscured by anchor driver 272. Following anchoring, proximal portion 262 is released by the deployment tool, and delivery tube 256 and driver 272 are withdrawn (state D).
It is to be noted that when prosthetic valve support 252 is disposed within delivery tube 256, the delivery tube and the prosthetic valve support (e.g., upstream support portion 254 thereof) share a common central longitudinal axis (e.g., are coaxial) (e.g., axis 258;
Prosthetic valve support 252 is typically subsequently used to facilitate implantation of a prosthetic valve, such as a prosthetic valve described hereinabove, or another prosthetic valve, e.g., by the prosthetic valve being expanded within the opening defined by the prosthetic valve support.
Reference is again made to
Reference is again made to
Reference is again made to
Reference is again made to
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application claims priority from U.S. Provisional Patent Application 61/756,034 to Hacohen et al., filed Jan. 24, 2013, and entitled “Tissue-engaging elements”; and U.S. Provisional Patent Application 61/756,049 to Hacohen et al., filed Jan. 24, 2013, and entitled “Ventricularly-anchored prosthetic valve support”, and is related to: US patent application publication 2012/0022639 to Hacohen et al., filed Jul. 21, 2010; US patent application publication 2012/0022640 to Gross et al., filed Feb. 24, 2011; U.S. patent application Ser. No. 13/811,308 to Gross et al., filed Jan. 21, 2013, which published as US 2013/0172992; U.S. patent application Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, which published as US 2013/0035759; PCT patent application IL2012/000292 to Gross et al., filed Aug. 5, 2012, which published as WO/2013/021374; PCT patent application IL2012/000293 to Gross et al., filed Aug. 5, 2012, which published as WO/2013/021375; and a PCT patent application to HaCohen et al., entitled “Ventricularly-anchored prosthetic valves”, filed on even date herewith, which was assigned PCT application number IL2014/050087, and which published as WO/2014/115149, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4261342 | Aranguren Duo | Apr 1981 | A |
4423525 | Vallana et al. | Jan 1984 | A |
4853986 | Allen | Aug 1989 | A |
4892541 | Alonso | Jan 1990 | A |
5108420 | Marks | Apr 1992 | A |
5405378 | Strecker | Apr 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5607444 | Lam | Mar 1997 | A |
5607470 | Milo | Mar 1997 | A |
5647857 | Anderson et al. | Jul 1997 | A |
5702397 | Goble et al. | Dec 1997 | A |
5765682 | Bley et al. | Jun 1998 | A |
5868777 | Lam | Feb 1999 | A |
5873906 | Lau et al. | Feb 1999 | A |
5980565 | Jayaraman | Nov 1999 | A |
6019787 | Richard et al. | Feb 2000 | A |
6042607 | Williamson, IV et al. | Mar 2000 | A |
6074417 | Peredo | Jun 2000 | A |
6120534 | Ruiz | Sep 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6187020 | Zegdi et al. | Feb 2001 | B1 |
6193745 | Fogarty et al. | Feb 2001 | B1 |
6287339 | Vazquez et al. | Sep 2001 | B1 |
6332893 | Mortier et al. | Dec 2001 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6352561 | Leopold et al. | Mar 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6419696 | Ortiz et al. | Jul 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6530952 | Vesely | Mar 2003 | B2 |
6540782 | Snyders | Apr 2003 | B1 |
6551350 | Thornton et al. | Apr 2003 | B1 |
6558396 | Inoue | May 2003 | B1 |
6558418 | Carpentier et al. | May 2003 | B2 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6699256 | Logan et al. | Mar 2004 | B1 |
6716244 | Klaco | Apr 2004 | B2 |
6719781 | Kim | Apr 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6797002 | Spence et al. | Sep 2004 | B2 |
6821297 | Snyders | Nov 2004 | B2 |
6830585 | Artof et al. | Dec 2004 | B1 |
6830638 | Boylan et al. | Dec 2004 | B2 |
6960217 | Bolduc | Nov 2005 | B2 |
6964684 | Ortiz et al. | Nov 2005 | B2 |
7011681 | Vesely | Mar 2006 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7041132 | Quijano et al. | May 2006 | B2 |
7077861 | Spence | Jul 2006 | B2 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7172625 | Shu et al. | Feb 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7288111 | Holloway et al. | Oct 2007 | B1 |
7329279 | Haug et al. | Feb 2008 | B2 |
7335213 | Hyde et al. | Feb 2008 | B1 |
7351256 | Hojeibane et al. | Apr 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7377938 | Sarac et al. | May 2008 | B2 |
7404824 | Webler et al. | Jul 2008 | B1 |
7422603 | Lane | Sep 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7445630 | Lashinski et al. | Nov 2008 | B2 |
7455677 | Vargas et al. | Nov 2008 | B2 |
7455688 | Furst et al. | Nov 2008 | B2 |
7462162 | Phan et al. | Dec 2008 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7513909 | Lane et al. | Apr 2009 | B2 |
7527646 | Rahdert et al. | May 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7625403 | Krivoruchko | Dec 2009 | B2 |
7632302 | Vreeman et al. | Dec 2009 | B2 |
7648528 | Styrc | Jan 2010 | B2 |
7682380 | Thornton et al. | Mar 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7717952 | Case et al. | May 2010 | B2 |
7717955 | Lane et al. | May 2010 | B2 |
7731741 | Eidenschink | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7753922 | Starksen | Jul 2010 | B2 |
7758595 | Allen et al. | Jul 2010 | B2 |
7758632 | Hojeibane et al. | Jul 2010 | B2 |
7771467 | Svensson | Aug 2010 | B2 |
7771469 | Liddicoat | Aug 2010 | B2 |
7776083 | Vesely | Aug 2010 | B2 |
7780726 | Seguin | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7803181 | Furst et al. | Sep 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7842081 | Yadin | Nov 2010 | B2 |
7850725 | Vardi et al. | Dec 2010 | B2 |
7871432 | Bergin | Jan 2011 | B2 |
7871436 | Ryan et al. | Jan 2011 | B2 |
7887583 | Macoviak | Feb 2011 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7896915 | Guyenot et al. | Mar 2011 | B2 |
7914544 | Nguyen et al. | Mar 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7927370 | Webler et al. | Apr 2011 | B2 |
7942927 | Kaye et al. | May 2011 | B2 |
7947072 | Yang et al. | May 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7955375 | Agnew | Jun 2011 | B2 |
7955377 | Melsheimer | Jun 2011 | B2 |
7955384 | Rafiee et al. | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7967833 | Sterman et al. | Jun 2011 | B2 |
7967857 | Lane | Jun 2011 | B2 |
7981151 | Rowe | Jul 2011 | B2 |
7981153 | Fogarty et al. | Jul 2011 | B2 |
7992567 | Hirotsuka et al. | Aug 2011 | B2 |
7993393 | Carpentier et al. | Aug 2011 | B2 |
8002825 | Letac et al. | Aug 2011 | B2 |
8002826 | Seguin | Aug 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8016882 | Macoviak et al. | Sep 2011 | B2 |
8021420 | Dolan | Sep 2011 | B2 |
8021421 | Fogarty et al. | Sep 2011 | B2 |
8029518 | Goldfarb et al. | Oct 2011 | B2 |
8029564 | Johnson et al. | Oct 2011 | B2 |
8034104 | Carpentier et al. | Oct 2011 | B2 |
8043360 | McNamara et al. | Oct 2011 | B2 |
8048138 | Sullivan et al. | Nov 2011 | B2 |
8048140 | Purdy | Nov 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052741 | Bruszewski et al. | Nov 2011 | B2 |
8057493 | Goldfarb et al. | Nov 2011 | B2 |
8057532 | Hoffman | Nov 2011 | B2 |
8057540 | Letac et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8062359 | Marquez et al. | Nov 2011 | B2 |
8070708 | Rottenberg et al. | Dec 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
8070804 | Hyde et al. | Dec 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
8080054 | Rowe | Dec 2011 | B2 |
8083793 | Lane et al. | Dec 2011 | B2 |
8092518 | Schreck | Jan 2012 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8092521 | Figulla et al. | Jan 2012 | B2 |
8105377 | Liddicoat | Jan 2012 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8118866 | Herrmann et al. | Feb 2012 | B2 |
8136218 | Millwee et al. | Mar 2012 | B2 |
8137398 | Tuval et al. | Mar 2012 | B2 |
8142492 | Forster et al. | Mar 2012 | B2 |
8142494 | Rahdert et al. | Mar 2012 | B2 |
8142496 | Berreklouw | Mar 2012 | B2 |
8142497 | Friedman | Mar 2012 | B2 |
8147504 | Ino et al. | Apr 2012 | B2 |
8157852 | Bloom et al. | Apr 2012 | B2 |
8157853 | Laske et al. | Apr 2012 | B2 |
8157860 | McNamara et al. | Apr 2012 | B2 |
8163008 | Wilson et al. | Apr 2012 | B2 |
8163014 | Lane et al. | Apr 2012 | B2 |
8167894 | Miles et al. | May 2012 | B2 |
8167932 | Bourang et al. | May 2012 | B2 |
8167935 | McGuckin, Jr. et al. | May 2012 | B2 |
8172896 | McNamara et al. | May 2012 | B2 |
8172898 | Alferness et al. | May 2012 | B2 |
8177836 | Lee et al. | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8211169 | Lane et al. | Jul 2012 | B2 |
8221492 | Case et al. | Jul 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8231670 | Salahieh et al. | Jul 2012 | B2 |
8236045 | Benichou et al. | Aug 2012 | B2 |
8236049 | Rowe et al. | Aug 2012 | B2 |
8252042 | McNamara et al. | Aug 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8257390 | Carley et al. | Sep 2012 | B2 |
8267988 | Hamer et al. | Sep 2012 | B2 |
8277501 | Chalekian et al. | Oct 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
8298280 | Yadin et al. | Oct 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8317853 | Agnew | Nov 2012 | B2 |
8317855 | Gregorich et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8328868 | Paul et al. | Dec 2012 | B2 |
8343174 | Goldfarb et al. | Jan 2013 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8403981 | Forster et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8425593 | Braido et al. | Apr 2013 | B2 |
8430934 | Das | Apr 2013 | B2 |
8444689 | Zhang | May 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449625 | Campbell et al. | May 2013 | B2 |
8454686 | Alkhatib | Jun 2013 | B2 |
8545544 | Spenser et al. | Oct 2013 | B2 |
8551161 | Dolan | Oct 2013 | B2 |
8562672 | Bonhoeffer et al. | Oct 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8579965 | Bonhoeffer et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8585756 | Bonhoeffer et al. | Nov 2013 | B2 |
8591570 | Revuelta et al. | Nov 2013 | B2 |
8623075 | Murray, III et al. | Jan 2014 | B2 |
8628569 | Benichou et al. | Jan 2014 | B2 |
8628570 | Seguin | Jan 2014 | B2 |
8628571 | Hacohen et al. | Jan 2014 | B1 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8696742 | Pintor et al. | Apr 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8784472 | Eidenschink | Jul 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8795355 | Alkhatib | Aug 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8808366 | Braido et al. | Aug 2014 | B2 |
8840664 | Karapetian et al. | Sep 2014 | B2 |
8852261 | White | Oct 2014 | B2 |
8852272 | Gross et al. | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8870949 | Rowe | Oct 2014 | B2 |
8870950 | Hacohen | Oct 2014 | B2 |
8888843 | Khairkhahan et al. | Nov 2014 | B2 |
8894702 | Quadri et al. | Nov 2014 | B2 |
8906083 | Obermiller et al. | Dec 2014 | B2 |
8911455 | Quadri et al. | Dec 2014 | B2 |
8911489 | Ben-Muvhar | Dec 2014 | B2 |
8932343 | Alkhatib et al. | Jan 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8979922 | Jayasinghe et al. | Mar 2015 | B2 |
8986373 | Chau et al. | Mar 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
8998982 | Richter et al. | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9023100 | Quadri et al. | May 2015 | B2 |
9034032 | McLean et al. | May 2015 | B2 |
9034033 | McLean et al. | May 2015 | B2 |
9039757 | McLean et al. | May 2015 | B2 |
9050188 | Schweich, Jr. et al. | Jun 2015 | B2 |
9072603 | Tuval et al. | Jul 2015 | B2 |
9084676 | Chau et al. | Jul 2015 | B2 |
9125738 | Figulla et al. | Sep 2015 | B2 |
9125740 | Morriss et al. | Sep 2015 | B2 |
9132006 | Spenser et al. | Sep 2015 | B2 |
9138312 | Tuval et al. | Sep 2015 | B2 |
9173738 | Murray, III et al. | Nov 2015 | B2 |
9220594 | Braido et al. | Dec 2015 | B2 |
9226820 | Braido et al. | Jan 2016 | B2 |
9226839 | Kariniemi et al. | Jan 2016 | B1 |
9232995 | Kovalsky et al. | Jan 2016 | B2 |
9241791 | Braido et al. | Jan 2016 | B2 |
9241794 | Braido et al. | Jan 2016 | B2 |
9248014 | Lane et al. | Feb 2016 | B2 |
9289290 | Alkhatib et al. | Mar 2016 | B2 |
9289291 | Gorman, III et al. | Mar 2016 | B2 |
9295550 | Nguyen et al. | Mar 2016 | B2 |
9295552 | McLean et al. | Mar 2016 | B2 |
9301836 | Buchbinder et al. | Apr 2016 | B2 |
D755384 | Pesce et al. | May 2016 | S |
9326852 | Spenser | May 2016 | B2 |
9421098 | Gifford, III et al. | Aug 2016 | B2 |
9427316 | Schweich, Jr. et al. | Aug 2016 | B2 |
9532870 | Cooper et al. | Jan 2017 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010056295 | Solem | Dec 2001 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020099436 | Thornton et al. | Jul 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20030036791 | Philipp et al. | Feb 2003 | A1 |
20030074052 | Besselink | Apr 2003 | A1 |
20030083742 | Spence et al. | May 2003 | A1 |
20030105519 | Fasol et al. | Jun 2003 | A1 |
20030158578 | Pantages et al. | Aug 2003 | A1 |
20040010272 | Manetakis et al. | Jan 2004 | A1 |
20040039414 | Carley et al. | Feb 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040122503 | Campbell et al. | Jun 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040143315 | Bruun et al. | Jul 2004 | A1 |
20040176839 | Huynh et al. | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040186566 | Hindrichs et al. | Sep 2004 | A1 |
20040210244 | Vargas et al. | Oct 2004 | A1 |
20040220593 | Greenhalgh | Nov 2004 | A1 |
20040225354 | Allen et al. | Nov 2004 | A1 |
20040249433 | Freitag | Dec 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20050004668 | Aklog et al. | Jan 2005 | A1 |
20050021056 | St. Goar et al. | Jan 2005 | A1 |
20050038494 | Eidenschink | Feb 2005 | A1 |
20050055086 | Stobie | Mar 2005 | A1 |
20050075731 | Artof et al. | Apr 2005 | A1 |
20050080430 | Wright, Jr. et al. | Apr 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050143809 | Salahieh et al. | Jun 2005 | A1 |
20050154443 | Linder et al. | Jul 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050197695 | Stacchino et al. | Sep 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050234508 | Cummins et al. | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050251251 | Cribier | Nov 2005 | A1 |
20050267573 | Macoviak et al. | Dec 2005 | A9 |
20060015171 | Armstrong | Jan 2006 | A1 |
20060020333 | Lashinski et al. | Jan 2006 | A1 |
20060047297 | Case | Mar 2006 | A1 |
20060089627 | Burnett et al. | Apr 2006 | A1 |
20060135964 | Vesely | Jun 2006 | A1 |
20060178700 | Quinn | Aug 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060190036 | Wendel et al. | Aug 2006 | A1 |
20060190038 | Carley et al. | Aug 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060201519 | Frazier et al. | Sep 2006 | A1 |
20060212111 | Case et al. | Sep 2006 | A1 |
20060241656 | Starksen et al. | Oct 2006 | A1 |
20060241748 | Lee et al. | Oct 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060271166 | Thill et al. | Nov 2006 | A1 |
20060271171 | McQuinn et al. | Nov 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20070016288 | Gurskis et al. | Jan 2007 | A1 |
20070027549 | Godin | Feb 2007 | A1 |
20070038295 | Case et al. | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070055340 | Pryor | Mar 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070118151 | Davidson | May 2007 | A1 |
20070162103 | Case et al. | Jul 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070162111 | Fukamachi et al. | Jul 2007 | A1 |
20070173932 | Cali et al. | Jul 2007 | A1 |
20070198077 | Cully et al. | Aug 2007 | A1 |
20070198097 | Zegdi | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070225759 | Thommen et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070233186 | Meng | Oct 2007 | A1 |
20070233237 | Krivoruchko | Oct 2007 | A1 |
20070239272 | Navia et al. | Oct 2007 | A1 |
20070255400 | Parravicini et al. | Nov 2007 | A1 |
20080004688 | Spenser et al. | Jan 2008 | A1 |
20080004697 | Lichtenstein et al. | Jan 2008 | A1 |
20080051703 | Thornton et al. | Feb 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080077235 | Kirson | Mar 2008 | A1 |
20080082083 | Forde et al. | Apr 2008 | A1 |
20080086164 | Rowe | Apr 2008 | A1 |
20080086204 | Rankin | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080140003 | Bei et al. | Jun 2008 | A1 |
20080161910 | Revuelta et al. | Jul 2008 | A1 |
20080167705 | Agnew | Jul 2008 | A1 |
20080167714 | St. Goar et al. | Jul 2008 | A1 |
20080188929 | Schreck | Aug 2008 | A1 |
20080195200 | Vidlund et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080234814 | Salahieh et al. | Sep 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255580 | Hoffman et al. | Oct 2008 | A1 |
20080262609 | Gross et al. | Oct 2008 | A1 |
20080281411 | Berreklouw | Nov 2008 | A1 |
20080294234 | Hartley et al. | Nov 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090054969 | Salahieh et al. | Feb 2009 | A1 |
20090099650 | Bolduc et al. | Apr 2009 | A1 |
20090112159 | Slattery et al. | Apr 2009 | A1 |
20090171363 | Chocron | Jul 2009 | A1 |
20090177278 | Spence | Jul 2009 | A1 |
20090210052 | Forster et al. | Aug 2009 | A1 |
20090222081 | Linder et al. | Sep 2009 | A1 |
20090264994 | Saadat | Oct 2009 | A1 |
20090299449 | Styrc | Dec 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20090319037 | Rowe et al. | Dec 2009 | A1 |
20100023117 | Yoganathan et al. | Jan 2010 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100076548 | Konno | Mar 2010 | A1 |
20100114299 | Ben Muvhar et al. | May 2010 | A1 |
20100131054 | Tuval et al. | May 2010 | A1 |
20100137979 | Tuval et al. | Jun 2010 | A1 |
20100160958 | Clark | Jun 2010 | A1 |
20100161036 | Pintor et al. | Jun 2010 | A1 |
20100161042 | Maisano et al. | Jun 2010 | A1 |
20100174363 | Castro | Jul 2010 | A1 |
20100179643 | Shalev | Jul 2010 | A1 |
20100179648 | Richter et al. | Jul 2010 | A1 |
20100179649 | Richter et al. | Jul 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100222810 | DeBeer et al. | Sep 2010 | A1 |
20100228285 | Miles et al. | Sep 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
20100249908 | Chau et al. | Sep 2010 | A1 |
20100249917 | Zhang | Sep 2010 | A1 |
20100262232 | Annest | Oct 2010 | A1 |
20100280603 | Maisano et al. | Nov 2010 | A1 |
20100280606 | Naor | Nov 2010 | A1 |
20100324595 | Linder et al. | Dec 2010 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110015729 | Jimenez et al. | Jan 2011 | A1 |
20110015731 | Carpentier et al. | Jan 2011 | A1 |
20110022165 | Oba et al. | Jan 2011 | A1 |
20110040374 | Goetz et al. | Feb 2011 | A1 |
20110040375 | Letac et al. | Feb 2011 | A1 |
20110046662 | Moszner et al. | Feb 2011 | A1 |
20110054466 | Rothstein et al. | Mar 2011 | A1 |
20110054596 | Taylor | Mar 2011 | A1 |
20110054598 | Johnson | Mar 2011 | A1 |
20110071626 | Wright et al. | Mar 2011 | A1 |
20110077730 | Fenster | Mar 2011 | A1 |
20110082538 | Dahlgren et al. | Apr 2011 | A1 |
20110087322 | Letac et al. | Apr 2011 | A1 |
20110093063 | Schreck | Apr 2011 | A1 |
20110106247 | Miller et al. | May 2011 | A1 |
20110112625 | Ben-Muvhar et al. | May 2011 | A1 |
20110112632 | Chau et al. | May 2011 | A1 |
20110118830 | Liddicoat et al. | May 2011 | A1 |
20110125257 | Seguin et al. | May 2011 | A1 |
20110125258 | Centola | May 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110137409 | Yang et al. | Jun 2011 | A1 |
20110137410 | Hacohen | Jun 2011 | A1 |
20110166636 | Rowe | Jul 2011 | A1 |
20110172784 | Richter et al. | Jul 2011 | A1 |
20110178597 | Navia et al. | Jul 2011 | A9 |
20110184510 | Maisano et al. | Jul 2011 | A1 |
20110190877 | Lane et al. | Aug 2011 | A1 |
20110190879 | Bobo et al. | Aug 2011 | A1 |
20110202076 | Richter | Aug 2011 | A1 |
20110208283 | Rust | Aug 2011 | A1 |
20110208293 | Tabor | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110213461 | Seguin et al. | Sep 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110218620 | Meiri et al. | Sep 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110238159 | Guyenot et al. | Sep 2011 | A1 |
20110245911 | Quill et al. | Oct 2011 | A1 |
20110245917 | Savage et al. | Oct 2011 | A1 |
20110251675 | Dwork | Oct 2011 | A1 |
20110251676 | Sweeney et al. | Oct 2011 | A1 |
20110251678 | Eidenschink et al. | Oct 2011 | A1 |
20110251679 | Wiemeyer et al. | Oct 2011 | A1 |
20110251680 | Tran et al. | Oct 2011 | A1 |
20110251682 | Murray, III et al. | Oct 2011 | A1 |
20110251683 | Tabor | Oct 2011 | A1 |
20110257721 | Tabor | Oct 2011 | A1 |
20110257729 | Spenser et al. | Oct 2011 | A1 |
20110257736 | Marquez et al. | Oct 2011 | A1 |
20110257737 | Fogarty et al. | Oct 2011 | A1 |
20110264191 | Rothstein | Oct 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20110264198 | Murray, III et al. | Oct 2011 | A1 |
20110264199 | Tran et al. | Oct 2011 | A1 |
20110264200 | Tran et al. | Oct 2011 | A1 |
20110264201 | Yeung et al. | Oct 2011 | A1 |
20110264202 | Murray, III et al. | Oct 2011 | A1 |
20110264203 | Dwork et al. | Oct 2011 | A1 |
20110264206 | Tabor | Oct 2011 | A1 |
20110264208 | Duffy et al. | Oct 2011 | A1 |
20110270276 | Rothstein et al. | Nov 2011 | A1 |
20110271967 | Mortier et al. | Nov 2011 | A1 |
20110282438 | Drews et al. | Nov 2011 | A1 |
20110282439 | Thill et al. | Nov 2011 | A1 |
20110282440 | Cao et al. | Nov 2011 | A1 |
20110283514 | Fogarty et al. | Nov 2011 | A1 |
20110288634 | Tuval et al. | Nov 2011 | A1 |
20110295363 | Girard et al. | Dec 2011 | A1 |
20110301688 | Dolan | Dec 2011 | A1 |
20110301701 | Padala et al. | Dec 2011 | A1 |
20110301702 | Rust et al. | Dec 2011 | A1 |
20110313452 | Carley et al. | Dec 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20110319991 | Hariton et al. | Dec 2011 | A1 |
20120010694 | Lutter et al. | Jan 2012 | A1 |
20120022633 | Olson et al. | Jan 2012 | A1 |
20120022637 | Ben-Muvhar | Jan 2012 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120022640 | Gross et al. | Jan 2012 | A1 |
20120035703 | Lutter et al. | Feb 2012 | A1 |
20120035713 | Lutter et al. | Feb 2012 | A1 |
20120035722 | Tuval | Feb 2012 | A1 |
20120041547 | Duffy et al. | Feb 2012 | A1 |
20120041551 | Spenser et al. | Feb 2012 | A1 |
20120046738 | Lau et al. | Feb 2012 | A1 |
20120046742 | Tuval et al. | Feb 2012 | A1 |
20120053682 | Kovalsky et al. | Mar 2012 | A1 |
20120053688 | Fogarty et al. | Mar 2012 | A1 |
20120059454 | Millwee et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120078357 | Conklin | Mar 2012 | A1 |
20120083832 | Delaloye et al. | Apr 2012 | A1 |
20120083839 | Letac et al. | Apr 2012 | A1 |
20120083879 | Eberhardt et al. | Apr 2012 | A1 |
20120089223 | Nguyen et al. | Apr 2012 | A1 |
20120101570 | Tuval et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123511 | Brown | May 2012 | A1 |
20120123530 | Carpentier et al. | May 2012 | A1 |
20120130473 | Norris et al. | May 2012 | A1 |
20120130474 | Buckley | May 2012 | A1 |
20120130475 | Shaw | May 2012 | A1 |
20120136434 | Carpentier et al. | May 2012 | A1 |
20120150218 | Sandgren et al. | Jun 2012 | A1 |
20120165915 | Melsheimer et al. | Jun 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120197292 | Chin-Chen et al. | Aug 2012 | A1 |
20120283824 | Lutter et al. | Nov 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20120296360 | Norris et al. | Nov 2012 | A1 |
20120310328 | Olson | Dec 2012 | A1 |
20120323316 | Chau et al. | Dec 2012 | A1 |
20120330408 | Hillukka et al. | Dec 2012 | A1 |
20130006347 | McHugo | Jan 2013 | A1 |
20130018450 | Hunt | Jan 2013 | A1 |
20130035759 | Gross et al. | Feb 2013 | A1 |
20130041451 | Patterson et al. | Feb 2013 | A1 |
20130116780 | Miller et al. | May 2013 | A1 |
20130123896 | Bloss et al. | May 2013 | A1 |
20130123900 | Eblacas et al. | May 2013 | A1 |
20130150945 | Crawford et al. | Jun 2013 | A1 |
20130158647 | Norris et al. | Jun 2013 | A1 |
20130166017 | Cartledge et al. | Jun 2013 | A1 |
20130166022 | Conklin | Jun 2013 | A1 |
20130172978 | Vidlund et al. | Jul 2013 | A1 |
20130172992 | Gross et al. | Jul 2013 | A1 |
20130211501 | Buckley et al. | Aug 2013 | A1 |
20130245742 | Norris | Sep 2013 | A1 |
20130261737 | Costello | Oct 2013 | A1 |
20130297013 | Klima et al. | Nov 2013 | A1 |
20130304197 | Buchbinder et al. | Nov 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20140005778 | Buchbinder et al. | Jan 2014 | A1 |
20140018911 | Zhou et al. | Jan 2014 | A1 |
20140031928 | Murphy et al. | Jan 2014 | A1 |
20140046430 | Shaw | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140081376 | Burkart et al. | Mar 2014 | A1 |
20140106951 | Brandon | Apr 2014 | A1 |
20140120287 | Jacoby et al. | May 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140135894 | Norris et al. | May 2014 | A1 |
20140135895 | Andress et al. | May 2014 | A1 |
20140142681 | Norris | May 2014 | A1 |
20140148891 | Johnson | May 2014 | A1 |
20140163690 | White | Jun 2014 | A1 |
20140172069 | Roeder et al. | Jun 2014 | A1 |
20140188210 | Beard et al. | Jul 2014 | A1 |
20140194983 | Kovalsky et al. | Jul 2014 | A1 |
20140207231 | Hacohen et al. | Jul 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140257475 | Gross et al. | Sep 2014 | A1 |
20140277358 | Slazas | Sep 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140296962 | Cartledge et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20140358224 | Tegels et al. | Dec 2014 | A1 |
20140379065 | Johnson et al. | Dec 2014 | A1 |
20140379074 | Spence et al. | Dec 2014 | A1 |
20140379076 | Vidlund et al. | Dec 2014 | A1 |
20150045881 | Lim | Feb 2015 | A1 |
20150094802 | Buchbinder et al. | Apr 2015 | A1 |
20150127097 | Neumann et al. | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150173896 | Richter et al. | Jun 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150272730 | Melnick et al. | Oct 2015 | A1 |
20150327994 | Morriss et al. | Nov 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20160106539 | Buchbinder et al. | Apr 2016 | A1 |
20160220367 | Barrett | Aug 2016 | A1 |
20160242902 | Morriss et al. | Aug 2016 | A1 |
20160310268 | Oba et al. | Oct 2016 | A1 |
20160324640 | Gifford, III et al. | Nov 2016 | A1 |
Number | Date | Country |
---|---|---|
1264582 | Dec 2002 | EP |
9930647 | Jun 1999 | WO |
0047139 | Aug 2000 | WO |
0162189 | Aug 2001 | WO |
0187190 | Nov 2001 | WO |
2006054930 | May 2006 | WO |
2006070372 | Jul 2006 | WO |
2006089236 | Aug 2006 | WO |
2007059252 | May 2007 | WO |
2008013915 | Jan 2008 | WO |
2008029296 | Mar 2008 | WO |
2008070797 | Jun 2008 | WO |
2008103722 | Aug 2008 | WO |
2009033469 | Mar 2009 | WO |
2009053497 | Apr 2009 | WO |
2009091509 | Jul 2009 | WO |
2010006627 | Jan 2010 | WO |
2010081033 | Jul 2010 | WO |
2011069048 | Jun 2011 | WO |
2011106137 | Sep 2011 | WO |
2011111047 | Sep 2011 | WO |
2011137531 | Nov 2011 | WO |
2011143263 | Nov 2011 | WO |
2012011108 | Jan 2012 | WO |
2012024428 | Feb 2012 | WO |
2012127309 | Sep 2012 | WO |
2012177942 | Dec 2012 | WO |
2013021374 | Feb 2013 | WO |
2013021375 | Feb 2013 | WO |
2013059747 | Apr 2013 | WO |
2013078497 | Jun 2013 | WO |
2013128436 | Sep 2013 | WO |
2014164364 | Jan 2014 | WO |
2014022124 | Feb 2014 | WO |
2014145338 | Sep 2014 | WO |
2015173794 | Nov 2015 | WO |
2015191923 | Dec 2015 | WO |
2016093877 | Jun 2016 | WO |
Entry |
---|
U.S. Appl. No. 61/283,819, filed Dec. 8, 2009. |
U.S. Appl. No. 61/492,449, filed Jun. 2, 2011. |
U.S. Appl. No. 61/515,372, filed Aug. 5, 2011. |
U.S. Appl. No. 61/525,281, filed Aug. 19, 2011. |
U.S. Appl. No. 61/537,276, filed Sep. 21, 2011. |
U.S. Appl. No. 61/555,160, filed Nov. 3, 2011. |
U.S. Appl. No. 61/588,892, filed Jan. 20, 2012. |
U.S. Appl. No. 61/756,034, filed Jan. 24, 2013. |
U.S. Appl. No. 61/756,049, filed Jan. 24, 2013. |
USPTO NFOA dated May 29, 2012 in connection with U.S. Appl. No. 12/840,463. |
USPTO FOA dated Feb. 15, 2013 in connection with U.S. Appl. No. 12/840,463. |
USPTO NFOA dated Nov. 8, 2013 in connection with U.S. Appl. No. 12/840,463. |
USPTO NFOA dated Jun. 4, 2014 in connection with U.S. Appl. No. 12/840,463. |
USPTO RR dated Aug. 14, 2012 in connection with U.S. Appl. No. 12/961,721. |
USPTO NFOA dated Nov. 28, 2012 in connection with U.S. Appl. No. 12/961,721. |
USPTO NFOA dated Jun. 17, 2014 in connection with U.S. Appl. No. 12/961,721. |
USPTO FOA dated Jul. 23, 2013 in connection with U.S. Appl. No. 12/961,721. |
USPTO RR dated Jul. 2, 2012 in connection with U.S. Appl. No. 13/033,852. |
USPTO NFOA dated Nov. 23, 2012 in connection with U.S. Appl. No. 13/033,852. |
USPTO NFOA dated Aug. 2, 2013 in connection with U.S. Appl. No. 13/033,852. |
USPTO NFOA dated Jul. 3, 2014 in connection with U.S. Appl. No. 13/033,852. |
USPTO FOA dated Feb. 10, 2014 in connection with U.S. Appl. No. 13/033,852. |
USPTO RR dated Aug. 13, 2012 in connection with U.S. Appl. No. 13/044,694. |
USPTO NFOA dated Dec. 31, 2012 in connection with U.S. Appl. No. 13/044,694. |
USPTO NFOA dated Sep. 19, 2014 in connection with U.S. Appl. No. 13/044,694. |
USPTO FOA dated Jul. 18, 2013 in connection with U.S. Appl. No. 13/044,694. |
USPTO NFOA dated Feb. 6, 2013 in connection with U.S. Appl. No. 13/412,814. |
USPTO NFOA dated Sep. 12, 2013 in connection with U.S. Appl. No. 13/412,814. |
USPTO FOA dated May 23, 2014 in connection with U.S. Appl. No. 13/412,814. |
USPTO NOA mailed Aug. 15, 2014 in connection with U.S. Appl. No. 13/412,814. |
USPTO RR dated Feb. 3, 2014 in connection with U.S. Appl. No. 13/811,308. |
USPTO NFOA dated Jul. 2, 2014 in connection with U.S. Appl. No. 13/811,308. |
USPTO NFOA dated Dec. 10, 2015 in connection with U.S. Appl. No. 14/237,258. |
USPTO NFOA dated Jan. 21, 2016 in connection with U.S. Appl. No. 14/237,264. |
USPTO NFOA dated Nov. 27, 2015 in connection with U.S. Appl. No. 14/626,267. |
Extended European Search Report dated Feb. 18, 2015; Appln. No. 12821522.5-1651/2739214 PCT/IL2012000293. |
International Search Report and Written Opinion dated Oct. 19, 2015; PCT/IL2015/050792. |
Invitation to Pay Additional Fees dated Jun. 12, 2014: PCT/IL2014/050087. |
International Preliminary Report on Patentability dated Sep. 11, 2012; PCT/IL2011/000231. |
International Preliminary Report on Patentability dated Dec. 2, 2013; PCT/IL2011/000582. |
International Preliminary Report on Patentability dated Feb. 11, 2014; PCT/IL2012/000292. |
International Preliminary Report on Patentability dated Feb. 11, 2014; PCT/IL2012/000293. |
International Search Report and Written Opinion dated Oct. 13, 2011; PCT/IL11/00231. |
International Search Report and Written Opinion dated Dec. 5, 2011; PCT/IL11/00582. |
International Search Report and Written Opinion dated Feb. 6, 2013; PCT/IL12/000292. |
International Search Report and Written Opinion dated Feb. 6, 2013; PCT/IL12/000293. |
International Search Report and Written Opinion dated Mar. 17, 2014; PCT/IL13/50937. |
International Search Report and Written Opinion dated Sep. 4, 2014; PCT/IL2014/050087. |
Alexander S. Geha, MD, MS, et al; “Replacement of Degenerated Mitral and Aortic Bioprotheses Without Explantation”, Ann Thorac Surg: vol. 72, pp. 1509-1514; Nov. 2001. |
Dominique Himbert, MD, et al; “Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter Approaches and Outcomes”, 24 Pages, Oct. 28, 2013; TCT 25 Cardiovascular Research Foundation. |
J. Jansen, et al; “Detachable shape-memory sewing ring for heart valves”, Artificial Organs, vol. 16, pp. 294-297, 1992 (An abstract). |
Frank Langer, MD, et al;“RING plus STRING: Papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation”, The Journal of Thoracic and Cardiovascular Surgery, vol. 133, No. 1, pp. 247-249; Jan. 2007. |
Frank Langer, MD, et al; “RING+STRING Sucessful Repair Technique for Ischemic Mitral Regurgitation With Severe Leaflet Tethering”, Circulation, vol. 120[suppl 1]; S85-S91, Sep. 2009. |
John G. Webb MD, et al; “Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves”, Circulation, vol. 121, pp. 1848-1857; originally published online Apr. 12, 2010. |
International Search Report and Written Opinion dated May 30, 2016; Appln. No. PCT/IL2016/050125. |
USPTO RR dated Sep. 26, 2016 in connection with U.S. Appl. No. 14/763,004. |
Saturn Project; “A novel solution for transcatheter heart valve replacement specifically designed to address clinical therapeutic needs on mitral valve”, Dec. 2016, 8 pages. |
Righini Presentation EuroPCR May 2015 (Saturn)-downloaded from: https://www.pcronline.com/Cases-resourcesimages/Resources/Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-triscupid-valve-interventions; 18 pages. |
United Kingdom Office Action dated Feb. 8, 2017; Appln. GB1613219.3. |
European Patent Office—Office Action dated Feb. 10, 2017; Appln. 12 821 522.5-1651. |
USPTO NFOA dated Jan. 18, 2017 in connection with U.S. Appl. No. 14/626,267. |
USPTO NFOA dated Feb. 17, 2017 in connection with U.S. Appl. No. 14/689,608. |
Number | Date | Country | |
---|---|---|---|
20140207231 A1 | Jul 2014 | US |
Number | Date | Country | |
---|---|---|---|
61756034 | Jan 2013 | US | |
61756049 | Jan 2013 | US |